BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roshdy WH, Kandeil A, El-Shesheny R, Khalifa MK, Al-Karmalawy AA, Showky S, Naguib A, Elguindy N, Fahim M, Abu Elsood H, El Taweel A, Salamony A, Mohsen A, Kayali G, Ali MA, Kandeel A. Insight into Genetic Characteristics of Identified SARS-CoV-2 Variants in Egypt from March 2020 to May 2021. Pathogens 2022;11:834. [PMID: 35894057 DOI: 10.3390/pathogens11080834] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 El-Ghitany EM, Hashish MH, Farghaly AG, Omran EA, Osman NA, Fekry MM. Asymptomatic versus symptomatic SARS-CoV-2 infection: a cross-sectional seroprevalence study. Trop Med Health 2022;50:98. [PMID: 36575501 DOI: 10.1186/s41182-022-00490-9] [Reference Citation Analysis]
2 Osman NA, Hashish MH, Bakr WMK, Osman NA, Omran EA. "Day 25": a temporal indicator of stabilization of mortality risk among COVID-19 patients with high viral load. Trop Med Health 2022;50:92. [PMID: 36494866 DOI: 10.1186/s41182-022-00483-8] [Reference Citation Analysis]
3 El-ghitany EM, Hashish MH, Farghaly AG, Omran EA. Determining the SARS-CoV-2 Anti-Spike Cutoff Level Denoting Neutralizing Activity Using Two Commercial Kits. Vaccines 2022;10:1952. [DOI: 10.3390/vaccines10111952] [Reference Citation Analysis]
4 Antar SA, Saleh MA, Al-Karmalawy AA. Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2. Life Sci 2022;309:121048. [PMID: 36209833 DOI: 10.1016/j.lfs.2022.121048] [Reference Citation Analysis]